Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint Clarinex Switch Petition Assertions Are “Troubling” – NCL

This article was originally published in The Tan Sheet

Executive Summary

An FDA-mandated OTC switch of Schering-Plough's Clarinex (desloratadine) would be "troubling" and would represent "a serious shift in agency policy," the National Consumers League states

You may also be interested in...



Clarinex Clinical, Safety Characteristics Support OTC Use – WellPoint

The similar safety and efficacy profile of Schering-Plough's follow-on drug Clarinex (desloratadine) to other second-generation antihistamines makes it appropriate for OTC availability, WellPoint Health Networks asserts in an April 15 petition to FDA

OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS094831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel